Ignite Creation Date:
2024-05-06 @ 6:45 PM
Last Modification Date:
2024-10-26 @ 2:54 PM
Study NCT ID:
NCT05774808
Status:
COMPLETED
Last Update Posted:
2023-03-20
First Post:
2023-01-30
Brief Title:
Fate of Moderate Secondary Mitral Regurgitation in Patients Undergoing Aortic Valve Surgery for Severe Aortic Regurgitation
Sponsor:
Michele De Bonis
Organization:
Ospedale San Raffaele
Study Overview
Official Title:
Fate of Moderate Secondary Mitral Regurgitation in Patients Undergoing Aortic Valve Surgery for Severe Aortic Regurgitation
Status:
COMPLETED
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with severe aortic regurgitation AR may be affected in many cases by a concomitant moderate or severe mitral regurgitation MR Tethering of the mitral valve leaflets andor annular dilatation both consequences of left ventricular dilatation represent the most common mechanisms underlying the development of MR which can therefore be defined as secondary in this case
When both mitral and aortic regurgitation are severe patients show a decreased survival due to the pathophysiological consequences of the combination of these pathological conditions In this case surgery on both diseased valves is required to interrupt the natural history of the disease and is widely supported by current guidelines On the other hand little is known about the fate and prognostic implications of moderate MR secondary to severe AR and whether or not it should be treated at the time of aortic valve surgery For this condition the current guidelines do not provide specific recommendations referring generically to the decision of the Heart Team
To date there are few data describing the evolution of moderate MR in patients undergoing surgery for severe AR and insufficient data to support recommendations regarding the treatment of moderate MR concurrently with treatment of AR so that this decision is now entrusted to the evaluation of the Heart Team It is therefore desirable to evaluate the outcomes of these patients
The aim of this study is to evaluate the short- and long-term fate of secondary moderate MR in patients undergoing aortic valve replacement for severe AR
When both mitral and aortic regurgitation are severe patients show a decreased survival due to the pathophysiological consequences of the combination of these pathological conditions In this case surgery on both diseased valves is required to interrupt the natural history of the disease and is widely supported by current guidelines On the other hand little is known about the fate and prognostic implications of moderate MR secondary to severe AR and whether or not it should be treated at the time of aortic valve surgery For this condition the current guidelines do not provide specific recommendations referring generically to the decision of the Heart Team
To date there are few data describing the evolution of moderate MR in patients undergoing surgery for severe AR and insufficient data to support recommendations regarding the treatment of moderate MR concurrently with treatment of AR so that this decision is now entrusted to the evaluation of the Heart Team It is therefore desirable to evaluate the outcomes of these patients
The aim of this study is to evaluate the short- and long-term fate of secondary moderate MR in patients undergoing aortic valve replacement for severe AR
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None